SWX:NOVNPharmaceuticals
Novartis Oncology Data Highlights Scemblix Momentum And Radioligand Growth Potential
Novartis (SWX:NOVN) reported long term clinical data for Scemblix showing sustained superior efficacy and a favorable safety profile in chronic myeloid leukemia.
The company also released expanded clinical evidence for Pluvicto in prostate cancer, underscoring progress in its radioligand therapy franchise.
These data come from pivotal clinical trials and mark important milestones for Novartis in hematology and oncology.
For investors tracking large pharma, these updates touch two core...